Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...
The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints - The primary endpoint was met with 76% of participants administered ...
New study shows that targeting an oft-drugged family of cell membrane receptors with biased modulators can expand potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback